Spectrum Pharmaceuticals Articles

Ligand to earn up to $50 million in deal with Spectrum for Captisol-enabled melphalan

14 March 2013

Global epigenetic therapies market to increase at a CAGR of 10% through 2017

4 March 2013

Spectrum regains rights from Allergan for apaziquone

3 February 2013

Topotarget says belinostat pivotal trial meets primary endpoint

26 September 2012

Spectrum extends tender offer for Allos

9 July 2012

Spectrum plunges on negative trial results; makes bid for Allos

10 April 2012

Spectrum in-licenses novel GCSF drug from Hanmi Pharma

1 February 2012

Spectrum Pharma to acquire non-US rights to market Zevalin

26 January 2012

Spectrum upbeat on lymphoma drug Zevalin study

24 January 2012

Alnylam and Spectrum both name new chief medical officers

14 June 2011

US FDA approves J&J’s Zytiga for late-stage prostate cancer and Spectrum’s Fusilev for metastatic colorectal cancer

3 May 2011

Spectrum Pharma links with Viropro to develop biosimilar of Roche blockbuster drug rituximab; FDA expands use of Roche’s Actemra

6 January 2011

Showing 1-12 of 12 articles

Go to beginningPrevious
  • 1
NextGo to end